#USA #San Diego #Cancer Treatment #Aethlon Medical #Hemopurifier

Aethlon Medical Announces $4.5 Million Public Offering

Aethlon Medical, Inc. (NASDAQ: AEMD), a leading name in medical therapeutics, has revealed plans to raise $4.5 million through a newly priced public offering. This initiative highlights the company's commitment to advancing innovative treatments aimed at tackling cancer and life-threatening infectious diseases.

On September 4, 2025, Aethlon Medical confirmed that it will offer a total of 5,000,000 shares of its common stock, which may also include pre-funded warrants. Additionally, the company will provide accompanying warrants, allowing purchasers to buy up to an equal number of shares at a simultaneous offering price of $0.90 per share or pre-funded warrant. Notably, these warrants can be exercised immediately upon issuance, offering investors flexibility and potential benefits.

The offering is projected to close around September 5, 2025, pending customary closing conditions. Aethlon is working with Maxim Group LLC, acting as the exclusive placement agent for this endeavor. Gross proceeds from this offering are anticipated to be approximately $4.5 million before deducting fees associated with the placement agent and other expenses related to the offering.

Intended Use of Proceeds

Aethlon Medical has clearly outlined its intentions for utilizing the raised funds. The net proceeds from this offering are expected to support various general corporate needs, covering areas that encompass clinical trial expenditures, ongoing research and development, as well as necessary capital and operational spending. This strategic financial planning is part of Aethlon’s broader mission to tackle some of the medical field's most pressing challenges.

Regulatory Framework

The shares in this offering are being issued under a registration statement on Form S-1, which has been approved by the U.S. Securities and Exchange Commission (SEC) as of September 4, 2024. The offering will be conducted in accordance with a prospectus that is a component of the registration statement, ensuring transparency and compliance with securities regulations. Interested parties can access the preliminary prospectus filed with the SEC on their official website.

Overview of Aethlon Medical

Aethlon Medical is based in San Diego, California, and is primarily focused on developing the Hemopurifier, a novel medical device aimed at providing solutions for unmet needs in oncology and infectious disease treatment. The Hemopurifier is designed to selectively filter out pathogenic targets from biological fluids, showcasing Aethlon’s innovative approach to disease management. Their commitment to medical progress is further demonstrated through research collaborations aimed at exploring other possible applications for the Hemopurifier.

For stakeholders and interested investors, Aethlon Medical remains a pivotal entity in the medical device and therapeutic landscape, seeking to drive advancements that can positively impact patients’ lives. The company’s forward-looking strategies underline its dedication to not just addressing existing medical problems but also paving the way for future innovation in health care.

Conclusion

This public offering represents a significant opportunity for Aethlon Medical to enhance its financial footing as it continues to push boundaries in therapeutic solutions. With the medical landscape evolving rapidly, the successful execution of this offering will play a crucial role in advancing Aethlon’s mission to develop life-saving treatments for serious health conditions. As the closing date approaches, stakeholders will be looking keenly at the developments from Aethlon Medical, with an eye toward the implications for cancer care and infectious disease treatment strategies.